Lymphocyte subset percentages were analyzed before initial treatment. EDTA anticoagulated peripheral blood (2 ml) were collected from patients with COVID-19 on admission (18 (link)). All samples were tested within 6 h of being obtained. Briefly, CD3+ total T-lymphocytes, CD19+ B-cell, CD3+/CD4+/CD8+ T-cell, and CD16+CD56+ NK-cell counts (cells/μl) were measured by multiple-color flow cytometry with human monoclonal anti-CD19-PE, anti-CD3-fluorescein isothiocyanate (FITC), anti-CD4-phycoerythrin (PE), anti-CD8-allophycocyanin (APC), anti-CD16-APC, and anti-CD56-PE antibodies (BD Multitest) according to the manufacturer's instructions. The cells were analyzed on a Partec Cube 6 Flow cytometry system (Sysmex Europe GmbH, Germany).
Free full text: Click here